Insider Transactions in Q2 2021 at Black Diamond Therapeutics, Inc. (BDTX)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2021
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
1,255
+14.44%
|
$15,060
$12.95 P/Share
|
|
Jun 18
2021
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
1,014
+39.38%
|
$12,168
$12.95 P/Share
|
|
May 20
2021
|
Rajeev M. Shah |
SELL
Other acquisition or disposition
|
Direct |
443
-100.0%
|
$10,632
$24.01 P/Share
|
|
May 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-12.0%
|
$110,106
$27.4 P/Share
|
|
May 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
May 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-43.86%
|
$65,000
$26.64 P/Share
|
|
May 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Apr 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-32.68%
|
$101,950
$25.0 P/Share
|
|
Apr 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
Apr 05
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-43.86%
|
$62,500
$25.54 P/Share
|
|
Apr 05
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Apr 01
2021
|
Rajeev M. Shah |
BUY
Other acquisition or disposition
|
Indirect |
353,814
+13.44%
|
$8,491,536
$24.26 P/Share
|